文献速递肾癌与肾肿瘤

小原发肿瘤尺寸与转移性肾细胞癌预后相关:两项减瘤性肾切除队列的启示

The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy.
PubMed 文献 · Eur Urol Oncol · 2019-11-14

研究基于MSK(n=304)和IMDC(n=778)两个独立队列,评估减瘤性肾切除术后转移性肾细胞癌患者原发肿瘤大小与总生存的关系。结果显示透明细胞肿瘤≤4cm与总生存改善显著相关,MSK队列HR 0.35(0.17-0.72,p=0.004),IMDC队列HR 0.54(0.36-0.83,p=0.004),且关联呈非线性。

要点

  • 转移性透明细胞肾癌原发肿瘤≤4cm与减瘤性肾切除术后总生存改善相关。
  • 该关联在MSK和IMDC两个独立队列中均得到验证。
  • 原发肿瘤大小与生存的关联呈非线性,小肿瘤转移群体预后更好。

核心结论

  • 原发肿瘤≤4cm在行减瘤性肾切除的转移性透明细胞肾细胞癌患者中与总生存改善独立相关。
  • 原发肿瘤大小与生存的关联呈非线性,提示存在一组预后较好的小转移性肾癌。

研究设计与样本

  • 回顾性队列研究,查询MSK肾切除数据库1989至2016年M1期行减瘤性肾切除患者n=304。
  • 使用IMDC数据n=778进行验证。
  • 原发肿瘤大小取自病理报告,以≤4cm与更大肿块比较。

临床怎么用

  • 原发肿瘤大小可能有助于M1期肾细胞癌的风险分层,需进一步探索其在临床决策中的效用。

局限性

  • 研究未纳入被认为不适合手术的患者。
  • 存在潜在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: One of the main challenges in the management of renal cell carcinoma (RCC) is risk-stratifying patients who present with metastatic disease. Tumor size is an important predictor of survival in the localized setting; however, this feature has not been explored fully in patients presenting with M1 RCC. OBJECTIVE: To assess the impact of tumor size on survival in patients with metastatic RCC who underwent cytoreductive nephrectomy (CN). DESIGN, SETTING, AND PARTICIPANTS: We queried the Memorial Sloan Kettering (MSK) nephrectomy database for patients who presented with M1 disease and underwent CN between 1989 and 2016 (n=304). Primary tumor size was obtained from pathology reports. Data from the International Metastatic Database Consortium (IMDC) were used for validation purposes (n=778). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Overall survival (OS) estimates were computed using the Kaplan-Meier method. Cox regressions were used to test the association between tumor size and OS in univariate and multivariable analyses. Tumors ≤4cm were compared with larger masses. Secondary analyses were performed to assess the robustness of these findings. RESULTS AND LIMITATIONS: Clear cell tumors ≤4cm were significantly associated with improved OS in both the MSK (hazard ratio [HR]: 0.35, 0.17-0.72, p= 0.004) and IMDC (HR 0.54, 0.36-0.83, p= 0.004) cohorts. The association was observed even after adjusting for known prognostic factors (HR 0.40, 0.14-1.14, p= 0.09 and HR: 0.54, 0.33-0.90, p= 0.02 in the MSK and IMDC cohorts, respectively). Limitations of this study include the absence of patients who were considered poor surgical candidates as well as potential selection bias. CONCLUSIONS: The primary tumor size ≤4cm was independently associated with improved OS in patients with metastatic clear cell RCC who underwent CN. Additionally, the association between primary size and survival was found to be nonlinear. These findings suggest that there is a group of small metastatic RCCs that can convey a better overall prognosis. The potential role of primary tumor size when risk stratifying patients with M1 RCC should be explored further to determine its utility during clinical decision making. PATIENT SUMMARY: We evaluated the impact of small tumor size on prognosis in patients with metastatic kidney cancer who undergo removal of the primary tumor. Very small masses (≤4cm) were associated with better prognosis in patients with clear cell tumors.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. DiNatale RG, Xie W, Becerra MF, et al. The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. Eur Urol Oncol. 2019. PMID: 31735646. doi:10.1016/j.euo.2019.10.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。